We have previously shown than anakinra, an IL1 receptor antagonist, was effective in suppressing intestinal inflammation in two patients with deleterious IL10RA mutations and history of severe infantile-onset IBD (7), and, similarly, blocking IL-1 is effective in patients with MVK deficiency (26). Here, IL10RA is linked to inflammatory bowel disease.